PT-141 (Bremelanotide)

PT-141, generic name bremelanotide, is a small ring-shaped peptide built as an analog of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural signalling molecule your body uses to talk to a family of receptors called the melanocortin receptors. It activates several of those receptors, but at the doses people actually use the one that matters is MC4R (melanocortin receptor 4), which sits in a part of the hypothalamus that governs sexual desire. The FDA (Food and Drug Administration) approved it in 2019 under the brand name Vyleesi, as a 1.75 mg single-use autoinjector, for premenopausal women with acquired, generalized HSDD (hypoactive sexual desire disorder) — low desire that causes them marked distress and is not explained by another illness, a relationship problem or a medication. That is the only approved use anywhere. It is not approved for men, not approved for postmenopausal women, and the research-peptide vials sold as PT-141 are not the approved product.

• The approved use: acquired, generalized hypoactive sexual desire disorder in premenopausal women, taken on demand rather than daily
• Off-label use by men for erectile dysfunction, on the strength of small phase 1 and phase 2 trials from 2004 to 2008 that were never followed by an approval application
• Off-label use by men and women who describe the target as libido itself rather than erection, since the drug acts on desire pathways in the brain
• Reported off-label by clinicians for low desire linked to antidepressant use or to postmenopausal status, neither of which the approval covers
• Research use as a tool compound for studying melanocortin receptor biology and central control of sexual behaviour

Sildenafil and its relatives are plumbing: they widen the pipes so blood can fill tissue that has already been told to fill. PT-141 works a floor above that, in the wiring. It presses a switch in the hypothalamus that releases dopamine in the circuit your brain uses to register wanting, so the interest arrives first and the body follows. That is why it does nothing on its own in an empty room and why it can help people for whom the pipes were never the problem.

1. 45 minThe Vyleesi label tells you to inject at least 45 minutes before anticipated sexual activity. Nothing in the published trials supports expecting an effect sooner than that.
2. 2-4 hoursPlasma levels peak, and so does the transient blood pressure rise: the label records up to 6 mmHg systolic and 3 mmHg diastolic at this point, with heart rate falling by up to 5 beats per minute. Both usually return to baseline within 12 hours.
3. First 2 dosesNausea is most likely here and, according to the label, usually improves by the second dose. In the phase 3 programme 40 percent of women reported nausea, 13 percent took an anti-emetic for it and 8 percent stopped the drug because of it.
4. Week 4-24The two phase 3 RECONNECT trials measured their co-primary endpoints across 24 weeks of as-needed use. The average gains were statistically clear but numerically modest: about 0.35 points on the Female Sexual Function Index desire domain and about -0.33 on the distress item, compared with placebo.
5. Month 12+A 52-week open-label extension found the improvements held and no new safety signals appeared, but only 272 of the 684 women who entered it finished. Nothing published tells you what happens after stopping.

• Nausea, in about 40 percent of women in the integrated phase 3 data versus 1.3 percent on placebo; it was the most common reason for stopping the drug
• Flushing, about 20 percent versus 1.3 percent on placebo
• Injection site reactions, about 13 percent on the label and 5.4 percent versus 0.5 percent in the integrated double-blind analysis
• Headache, about 11 percent versus 1.9 percent on placebo
• Vomiting, about 5 percent
• A transient rise in blood pressure with a matching fall in heart rate after every dose, measured directly by ambulatory monitoring
• Focal hyperpigmentation — darkened patches of skin on the face, gums or breasts. About 1 percent at the labelled maximum of 8 doses a month, but more than a third of subjects when bremelanotide was given daily for up to 16 days. It is more likely with darker skin and may not fully resolve after stopping
• In the 52-week extension the same three events dominated: nausea 40.4 percent, flushing 20.6 percent and headache 12.0 percent, with nausea the only severe event reported by more than one participant in both studies

• You have uncontrolled hypertension or known cardiovascular disease — both are outright contraindications on the Vyleesi label, because the drug raises blood pressure after every dose
• You are pregnant or trying to conceive. Animal reproduction studies showed fetal harm at exposures 16 times human levels in dogs and 125 times in mice, and effective contraception is recommended during use
• You are breastfeeding, since there is no data on whether bremelanotide passes into human milk
• You take oral naltrexone for alcohol or opioid dependence; bremelanotide lowers its plasma concentration enough that the label says to avoid the combination
• You depend on a fast-acting oral medication such as indomethacin, because bremelanotide slows gastric emptying and delays absorption of oral drugs
• You are postmenopausal or male, in which case you are outside every population the approval was based on and there is no labelled dose for you
• You are not under the supervision of a physician who can check your blood pressure before starting and monitor it during use

• Treating it like a PDE5 inhibitor. It does not produce an erection on its own and does nothing without sexual stimulation; the male trials all used visual sexual stimulation or at-home attempts, never the drug in isolation
• Dosing it daily or close to daily. The label caps it at one dose per 24 hours and eight doses per month, and the hyperpigmentation rate jumps from roughly 1 percent at that cap to more than a third with consecutive daily dosing
• Skipping a blood pressure check. Uncontrolled hypertension and known cardiovascular disease are contraindications, and the ambulatory monitoring study exists precisely because MC4R agonism raises blood pressure
• Taking it right before the event. The label specifies at least 45 minutes ahead, and the transient pressure and nausea peak 2 to 4 hours in, so timing it badly means the side effects arrive at the worst moment
• Reconstituting a research vial with plain sterile water and then leaving it at room temperature. Bacteriostatic water added slowly down the vial wall, swirled not shaken, and refrigerated afterwards is the standard handling — and none of that makes an unregulated vial equivalent to the 1.75 mg autoinjector the trials used
• Stacking it with alcohol or with a PDE5 inhibitor without telling a doctor. The one published co-administration study used deliberately sub-therapeutic doses of both under supervision, not full doses of each